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Background: Red blood cells (RBCs) labeled with single-photon emitters have been clinically used for blood-pool
imaging. Although some PET tracers have been introduced for blood-pool imaging, they have not yet been widely
used. The present study investigated the feasibility of labeling RBCs with 18F-2-deoxy-2-fluoro-D-glucose (18F-FDG)
for blood-pool imaging with PET.
RBCs isolated from venous blood of rats were washed with glucose-free phosphate-buffered saline and labeled
with 18F-FDG. To optimize labeling efficiency, the effects of glucose deprivation time and incubation (labeling) time
with 18F-FDG were investigated. Post-labeling stability was assessed by calculating the release fraction of radioactivity
and identifying the chemical forms of 18F in the released and intracellular components of 18F-FDG-labeled RBCs
incubated in plasma. Just after intravenous injection of the optimized autologous 18F-FDG-labeled RBCs, dynamic PET
scans were performed to evaluate in vivo imaging in normal rats and intraabdominal bleeding models (temporary and
persistent bleeding).
Results: The optimal durations of glucose deprivation and incubation (labeling) with 18F-FDG were 60 and 30 min,
respectively. As low as 10% of 18F was released as the form of 18F-FDG from 18F-FDG-labeled RBCs after a 60-min
incubation. Dynamic PET images of normal rats showed strong persistence in the cardiovascular system for at least
120 min. In the intraabdominal bleeding models, 18F-FDG-labeled RBC PET visualized the extravascular blood clearly
and revealed the dynamic changes of the extravascular radioactivity in the temporary and persistent bleeding.
Conclusions: RBCs can be effectively labeled with 18F-FDG and used for blood-pool imaging with PET in rats.
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Nuclear medicine techniques using red blood cells
(RBCs) labeled with several single-photon emitters such
as 99mTc have been used for blood-pool imaging (BPI).
The purposes of BPI include the detection of gastro-
intestinal bleeding [1, 2], evaluation of cardiac function
[3, 4], localization of hemangiomas [5, 6], and regional
cerebral blood volume measurement [7]. RBCs would be
a more suitable tracer for BPI than radionuclide-labeled
plasma proteins because plasma proteins tend to leak* Correspondence: nakahara@rad.med.keio.ac.jp
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the Creative Commons license, and indicate ifinto extravascular spaces [8]. Since Fisher et al. reported
the first human study of 99mTc-labeled RBCs for splenic
radionuclide imaging 50 years ago [9], 99mTc-labeled
RBC scintigraphy has been clinically used for BPI. Fur-
thermore, single-photon emission computed tomography/
computed tomography (SPECT/CT) improves the ana-
tomical information of 99mTc-labeled RBC imaging [10].
Although positron emission tomography (PET) has bet-
ter image quality than scintigraphy and SPECT, blood-
pool agents for PET are limited. Carbon monoxide (CO)
labeled with 11C or 15O has been applied to RBC imaging
with PET [11, 12], but the short half-life of these radionu-
clides prevents their widespread use. Fluorine-18 seems
more suitable for PET BPI in terms of the longer half-lifeis distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
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have been a few reports which demonstrated the labeling
of RBCs with 18F-labeled compounds: 18F-sulfonamide de-
rivative [14] and 18F-N-succinimidyl 4-18F-fluorobenzoate
(18F-SFB) [13]. In these two reports, RBC PET was suc-
cessful in evaluation of cardiac function or blood volume
quantification, respectively.
Fluorine-18-2-deoxy-2-fluoro-D-glucose (18F-FDG) is
the most available PET tracer in the world. Fluorine-18-
FDG-labeled white blood cells (WBCs) have already been
clinically used as an inflammation-seeking agent [15–18].
Due to the absence of nuclei or mitochondria, glucose is
the only energy substrate for RBCs; thus, we speculated
that RBCs could be also labeled with 18F-FDG for imaging.
There has been evidence of transporting 18F-FDG into
RBCs in an equilibrium state [19, 20]. The aims of the
present study were to determine an optimal labeling
procedure for 18F-FDG-labeled RBCs and to demonstrate
the suitability of the RBC preparation for BPI using
in vivo rat imaging.
Methods
Animals
The entire experimental protocols were approved by the
Keio University Institutional Animal Care and Use Com-
mittee and performed in accordance with the Institutional
Guidelines on Animal Experimentation at Keio University.
Healthy male F344/Jcl rats were purchased from Clea
Japan Incorporation. The rats were given standard rat
chow and tap water ad libitum.
RBC preparation for in vitro studies
After a 3-h fasting period, the rats (weight, 188.7 ± 16 g)
were anesthetized with isoflurane. The inferior vena cava
(IVC) was exposed through an abdominal incision. A
23-gauge needle was placed in the IVC, and heparin
(1000 IU/kg body weight) was administered to prevent
blood coagulation. Thirty seconds later, the blood (4 ml)
was slowly withdrawn from the IVC. Blood glucose con-
centration was measured with a glucometer (Accu-Chek
Aviva; Roche Diagnostics Co., Ltd., Japan). The blood
was centrifuged at 500g for 10 min at 4 °C. The super-
natant (plasma) was stored for subsequent post-labeling
stability studies. The buffy coat, which contains most of
WBCs and platelets, was removed. To eliminate extra-
cellular glucose, the packed RBCs were washed three times
in the following way: RBCs were mixed with glucose-free
phosphate-buffered saline (PBS) (8 ml; Wako Pure
Chemical Industries, Ltd., Japan) and centrifuged at
1000g for 2 min, and the supernatant was removed.
After washing, the packed RBC suspension was uniformly
resuspended and the hematocrit was measured with the
microhematocrit technique after centrifuging at 12,000g
for 3 min [21, 22]. Hematocrit was adjusted to 2.5–80% bydiluting the packed RBCs with a calculated volume of
PBS.
Preparation of 18F-FDG
Fluorine-18-FDG was produced in a clinical routine setup
on-site. The specific radioactivity at the time of labeling
was approximately 500 GBq/μmol. The osmolarity of
18F-FDG solution was adjusted to prevent some RBCs from
rupture because of the hyposmosis of original 18F-FDG so-
lution (less than 4 mOsm/L). As previously performed in
the study of 18F-FDG-labeled WBCs by Osman et al. [15],
11 μL of 10X PBS (2800 mOsm/L; Wako Pure Chemical
Industries, Ltd., Japan) was added to 100 μL of 18F-FDG
solution.
Labeling efficiency analysis
We considered that labeling efficiency (LE) of 18F-FDG-
labeled RBCs would be influenced by the following
possible factors: depletion of intracellular glucose be-
fore labeling, hematocrit for labeling, and incubation
(labeling) time with 18F-FDG.
We hypothesized that LE could be increased by incu-
bating RBCs in glucose-free PBS at 37 °C before labeling,
which can reduce intracellular glucose concentration. To
investigate the effect of glucose deprivation before labeling,
the prepared RBC suspension (70% hematocrit, 100 μL)
was incubated at 37 °C for 0–120 min. The incubated RBC
suspension was mixed with 18F-FDG solution (12.0 ±
1.7 MBq, 15.3 ± 0.3 μL, n = 4) and incubated for 30 min at
37 °C for labeling. To eliminate extracellular 18F-FDG, the
labeled RBCs were washed three times at 4 °C with Hanks’
balanced salt solution (HBSS) (Wako Pure Chemical In-
dustries, Ltd., Japan) containing glucose (100 mg/dL). The
primary radioactivity of 18F-FDG and the radioactivity of
the labeled RBCs were measured with a dose calibrator
(Curiemeter IGC-7; Aloka, Japan). Then, LE was calculated
as a percentage by dividing the radioactivity of the labeled
RBCs by the primary radioactivity with decay correction.
The relationship between hematocrit for labeling and
LE was analyzed. The hematocrit of the prepared RBC
suspension was adjusted to 2.5–80%. After a 60-min
incubation at 37 °C for reducing intracellular glucose
concentration before labeling, each hematocrit suspension
(100 μL) was mixed with 18F-FDG solution (15.0 MBq,
14.6 μL) and incubated for 30 min at 37 °C for labeling.
Washing, radioactivity measurement, and LE calculation
were performed following the same procedure as de-
scribed above. In addition, the relationship between the
added radioactivity of 18F-FDG (7.3–20.1 MBq) and the
radioactivity of labeled RBCs was analyzed.
The effect of the labeling (incubation) time with 18F-FDG
on LE was investigated. The prepared RBC suspension
(100 μL, 70% hematocrit) was incubated for 60 min at
37 °C to reduce intracellular glucose concentration
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18F-FDG solution (11.1 ± 0.7 MBq, 14.3 ± 3.2 μL, n = 3).
The labeling times with 18F-FDG at 37 °C were varied
from 0 to 60 min at an interval of 5 min. Washing,
radioactivity measurement, and LE calculation were
performed following the same procedure as described
above. Based on the results of these analyses, the optimal
conditions for labeling RBCs with 18F-FDG were deter-
mined and then further experiments were performed.
Post-labeling stability of 18F-FDG-labeled RBCs
The post-labeling stability was assessed by calculating a
release fraction of radioactivity from 18F-FDG-labeled
RBCs. The washed RBC suspension (1.5 ml, 80%
hematocrit, n = 4) was incubated for 60 min at 37 °C to
reduce intracellular glucose concentration before label-
ing. The RBC suspension was mixed with 18F-FDG
(more than 100 MBq) and incubated for 30 min at 37 °C
for labeling. To eliminate extracellular 18F-FDG, the la-
beled RBCs were washed three times with HBSS at 4 °C.
The radioactivity of 18F-FDG-labeled RBCs was measured
with the dose calibrator. The labeled RBC suspension was
diluted with the plasma separated soon after blood sam-
pling, and its hematocrit was adjusted to 40%. The labeled
RBC suspension (200 μL, 40% hematocrit) was incubated
for 0–180 min at 37 and 0 °C. After each incubation time,
the labeled RBC suspension was cooled and uniformly re-
suspended. The whole RBC suspension (10 μL) was sam-
pled for radioactivity measurement. The remnant RBC
suspension was centrifuged at 1000g for 2 min, and the
supernatant (10 μL) was also sampled. The whole RBC
suspension and the supernatant were simultaneously mea-
sured with a well-type scintillation counter (ARC-380CL,
Aloka, Japan). The release fraction was calculated ac-
cording to the formula,




Radioactivity of whole RBC suspension
 100
, where hematocrit was 40%.
In addition, extracellular glucose concentration of the
supernatant during the 180-min incubation was measured
with a glucometer to check the uptake ratio of glucose by
RBCs at 37 and 0 °C.
Thin-layer chromatography
To estimate the chemical form of 18F released from
18F-FDG-labeled RBCs, thin-layer chromatography (TLC)
was performed. Fluorine-18-FDG-labeled RBC suspension
diluted with plasma (40% hematocrit, 200 μL) was pre-
pared following the same procedure used for the stability
study described above. After a 60-min incubation of the
18F-FDG-labeled RBC suspension at 37 °C, it was centri-
fuged at 1000g for 2 min at 4 °C. The supernatant was
spotted on to silica gel TLC strips (4 × 8 cm, Merck,Darmstadt, FRG). The packed RBCs were washed three
times with HBSS at 4 °C to eliminate extracellular radio-
activity, and the labeled RBCs were completely lysed with
distilled water. The lysate was spotted onto another TLC
strip. Original 18F-FDG solution was spotted as an authen-
tic sample. Acetonitrile/water (v/v = 95:5) was used as
eluent. Chromatograms were measured using a Typhoon
FLA 9000 imager (GE Healthcare Life Sciences). Fluorine-
18-FDG and 18F-FDG-6-phosphate were identified by
their Rf values (0.37 and 0, respectively) [23].Preparation of labeled RBCs for PET imaging
After a 3-h fasting period, the rats were anesthetized
with isoflurane. The blood (400 μL) was slowly withdrawn
from the cervical vein using a heparinized syringe with a
27-gauge needle. After blood sampling, the rats were re-
covered from anesthesia and replaced in their cages with-
out food. The blood was centrifuged at 500g for 5 min at
4 °C, and the buffy coat was removed. The packed RBC
suspension (100 μL, 80% hematocrit) was washed three
times with PBS. After a 60-min incubation in glucose-free
PBS at 37 °C for reducing intracellular glucose concentra-
tion, the RBCs was mixed with 18F-FDG solution (20.0 ±
8.4 MBq) and incubated for 30 min at 37 °C for labeling.
After labeling, 18F-FDG-labeled RBCs were washed
three times with HBSS at 4 °C to eliminate extracellular
18F-FDG. The LE was calculated with decay correction.
The packed labeled RBC suspension (100 μL) was di-
luted with HBSS, and the total volume was adjusted to
400 μL (20% hematocrit). The obtained labeled RBC
suspension was cooled and preserved at 0 °C until injec-
tion. In addition, the labeled RBCs were observed with a
microscope to evaluate their morphological abnormality.PET imaging of normal rats
The rats (169 ± 18g, n = 5) were anesthetized again and
maintained with isoflurane throughout the imaging pro-
cedure. Imaging was performed using a small-animal PET
system (ClairvivoPET; Shimadzu Corporation, Japan) [24].
The rats were placed in a supine position on a fixation
plate in the PET scanner. A transmission scan with an
external 137Cs point source (22 MBq) was performed
for attenuation correction. Autologous 18F-FDG-labeled
RBC suspension (10.5 ± 3.7 MBq, 400 μL, 20% hematocrit,
rewarmed at room temperature) was injected via the lat-
eral tail vein. Image acquisition was simultaneously
started, and list-mode data were acquired for 120 min.
The rectal temperature was kept at 36–38 °C by heating.
The list-mode data were reconstructed into a dynamic se-
quence (27 frames, 3 × 10, 5 × 30, 2 × 60, 11 × 300, and
6 × 600 s) using 3D-DRAMA (dynamic row-action
maximization-likelihood algorithm) with decay correction.
The matrix size was 128 × 128 × 213 pixels.
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We imaged intraabdominal bleeding models of rats as a
potential use of 18F-FDG-labeled RBC PET. Before PET
imaging, glycerin enema (1 mL) was transanally injected
into the colon for defecation. After a transmission scan,
autologous 18F-FDG-labeled RBC suspension (10 MBq,
400 μL) was intravenously injected, and image acquisition
was simultaneously started. List-mode data were acquired
for 40 min. In a steady-state of the BPI (20–25 min after
injection), a transanal puncture of the colonic wall was
manually given with an 18-gauge intravenous needle to in-
duce hemorrhage into the abdominal cavity. In the present
study, two kinds of bleeding models were imaged: persist-
ent and temporary bleeding models. To model a persistent
bleeding rat (171 g, n = 1), heparin (1000 IU/kg body
weight) was injected via the tail vein just before injection
of 18F-FDG-labeled RBCs, whereas no heparin was used
for a temporary bleeding model (170 g, n = 1). After PET
imaging, CT was performed using a micro CT system
(R-mCT; Rigaku, Japan) to localize the extravascular
blood inside the abdominal cavity. CT parameters were
as follows: X-ray source, 90 kV/100 μA; rotation, 360°;
exposure time, 17 s; and voxel size, 133 × 133 × 282 μm.
Image analysis
The reconstructed images were analyzed using PMOD
version 3.80 (PMOD Technologies Ltd, Switzerland). In
the images of normal rats, volumes of interest (VOIs) were
placed in each organ, and the radioactivity was expressed as
the percentage of injected dose per gram (%ID/g). Time-
activity curves (TACs) for the atrium, lung, liver, brain,
spleen, kidney, and urinary bladder were obtained.
In order to measure the radioactivity of bleeding in the
intraabdominal bleeding models, image subtraction was
performed between the post-bleeding images (38–40 min
after injection) and the pre-bleeding images (10–20 min
after injection) with an algebra tool of PMOD. Negative
values of the pixels in the subtracted images were all re-
placed to zero value. Then, the total radioactivity of bleed-
ing during PET imaging was measured as the percentage
of injected dose (%ID) after excluding radioactivity of the
urinary bladder.
Statistical analysis
Quantitative data were expressed as mean ± SD. Spearman’s
rank correlation coefficient was used to assess the quality of
linear correlations using the SPSS software package (version
22.0, SPSS Inc., IBM, Chicago, USA). A P value of less than
0.05 was considered statistically significant.
Results
Labeling efficiency
The blood glucose concentration soon after blood sam-
pling was 232 ± 30 mg/dL. In Fig. 1, LE under variouscircumstances is summarized. The LE increased with the
incubation time in PBS before labeling and was 37.6% in
0 min and 76.7% in 60 min (Fig. 1a). The higher the
hematocrit for labeling is, the higher the LE is (Fig. 1b).
At this time, there were technical difficulties accurately
measuring LE when hematocrit was over 80% because of
the high viscosity and the presence of dried-up RBCs
around fluid surface during a long incubation. Even
though LE continued to rise over labeling time (Fig. 1c),
the loss of radioactivity exceeded the increase in LE after
30–35 min and the net radioactivity began to decrease
after this time (Fig. 1d). There was a positive correlation
between 18F-FDG-added and 18F-FDG-labeled RBCs
(Additional file 1: Figure S1). Based on these results, we
determined that the optimal labeling conditions were as
follows: glucose depriving time was 60 min, hematocrit
for labeling was 70%, and labeling (incubation) time was
30 min.
Post-labeling stability of 18F-FDG-labeled RBCs
In Table 1, LE of 18F-FDG-labeled RBCs by means of the
optimized labeling procedure is shown. The obtained
radioactivity of 18F-FDG-labeled RBC suspension (1.5 mL)
was 89 ± 26 MBq, and the LE was 69.3 ± 13.3%. Figure 2
summarizes the post-labeling stability of 18F-FDG-labeled
RBCs. The release fraction of a chemical form of 18F in-
creased constantly for 3 h at 37 °C; no release was seen at
0 °C (Fig. 2a). The release fractions at 37 °C in 60, 120,
and 180 min incubation were 10.1, 15.8, and 20.5%, re-
spectively, which were larger than we expected. TLC of
extra- and intracellular fluid at 60 min of incubation
showed the 18F-FDG ratio of extracellular fluid (release)
was 92.6%, while that of intracellular fluid (hemolysis)
was 4.7% (Fig. 2b). Extracellular glucose concentration
gradually decreased at 37 °C but did not change at 0 °C
(Additional file 1: Figure S2).
Labeling for in vivo imaging
Labeling RBCs with 18F-FDG for in vivo imaging was
performed with the optimized procedure as shown in
Fig. 3. The average time from blood sampling to intra-
venous injection of 18F-FDG-labeled RBC suspension was
approximately 125 min. In microscopic images, 18F-FDG-
labeled RBCs appeared normal and no aggregation of
RBCs nor RBCs with abnormal shapes (e.g., spherocytes,
acanthocytes, or schistocytes) were seen (Additional file 1:
Figure S3). The radioactivity of the obtained 18F-FDG-
labeled RBC suspension (400 μL, 20% hematocrit) were
11.2 ± 3.9 MBq, and the LE was 71.7 ± 10.2% (n = 4).
PET imaging of normal rats
The maximum-intensity-projection images revealed that
the cardiac space and the vessels of whole bodies showed
a strong accumulation of 18F-FDG-labeled RBCs (Fig. 4a).
Fig. 1 Relationship between labeling efficiency and its influence factors. a Effect of the preparation of glucose deprivation before labeling on labeling
efficiency (labeling time, 30 min; n = 4). b Relationship between hematocrit for labeling and labeling efficiency. A positive linear correlation was found
(some dots overlap). c Relationship between labeling time with 18F-FDG and labeling efficiency (glucose deprivation time, 60 min; n = 3). d Relationship
between labeling time with 18F-FDG and the percentage of the actual radioactivity of 18F-FDG-labeled RBCs per the initial dose (the same data as
Fig. 1c expressed without decay correction)
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most organs was relatively constant up to 120 min
(Fig. 4b), suggesting that our procedure was appropriate
for BPI. The intraatrial radioactivity of 60 min decreased
only 5.6% compared to that of 5–10 min. Meanwhile,
slight urinary excretion was seen. The splenic radioactivity
was higher than the hepatic radioactivity and lower than
the pulmonary radioactivity during 30 min after injection.
Intraabdominal bleeding models
Dynamic PET images revealed the appearance of high
accumulation sites in the abdomen soon after the punc-
ture of the colon wall, suggesting the extravasation of
the tracer due to bleeding (Figs. 5a and 6a). Extravascu-
lar blood was not identified in the CT image (Figs. 5bTable 1 Labeling efficiency of 18F-FDG-labeled RBCs by the optimize
Prepared RBC suspension 18F-FDG used for labeling
1.5 ml (80% hematocrit) 166 ± 29 MBq
Data are mean ± SD (n = 4). The optimized labeling procedure is described in Fig. 3
aDecay correctedand 6b). The TAC of the extravascular blood in the
temporary bleeding model (without heparin) rose soon
after puncture of the colon wall and reached a plateau
in 4 min, while the TAC in the persistent model (with
heparin) rose continuously (Figs. 5c and 6c).
Discussion
To our knowledge, this is the first study demonstrating
the feasibility of labeling RBCs with 18F-FDG. In order
to apply 18F-FDG-labeled RBC PET to human study,
optimization or standardization of labeling procedure is
crucial in terms of the accuracy of 18F-FDG-labeled RBC
PET for BPI. Therefore, we sought the optimal labeling
procedure to achieve the highest LE and stability by
measuring LE in different conditions. In the optimizedd labeling procedure
18F-FDG-labeled RBCs Labeling efficiencya
89 ± 26 MBq 69.3 ± 13.3%
Fig. 2 Post-labeling stability analysis. a Release fraction of the radioactivity from 18F-FDG-labeled RBCs during a 180-min incubation in plasma at
37 or at 0 °C (n = 4). b Thin-layer chromatography of extra- (left, release) and intracellular fluid (right, hemolysis) after a 60-min incubation of
18F-FDG-labeled RBCs in plasma. Obvious difference between them was seen
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high retention of the tracer in the cardiovascular system
for at least 120 min in normal rats. In the intraabdominal
bleeding models, 18F-FDG-labeled RBC PET visualized the
extravascular blood more clearly than CT and revealed the
different patterns of the extravascular radioactivity be-
tween the temporary and persistent bleeding models.
We considered that high LE could be achieved by de-
priving glucose from RBCs. Glucose deprivation reduces
intracellular glucose concentration. In addition, a glucose
concentration gradient across the membrane is the driving
force to transport glucose via glucose transporter-1 on the
plasma membrane of RBCs [25]. Taken together, this pre-
labeling preparation can boost the uptake of glucose or
18F-FDG into RBCs. Indeed, our results showed that glu-
cose deprivation for up to 60 min significantly improved
the LE (Fig. 1a). Considering the balance between the LE
and the potential cell damage due to prolonged glucose
deprivation, the duration of glucose deprivation was set at
60 min in subsequent studies. Higher hematocrit was
suitable for achieving higher LE (Fig. 1b). However, it
was practically difficult to uniformly mix high-hematocritFig. 3 An optimal labeling procedure of 18F-FDG-labeled RBCs for in vivo iRBC suspension (over 80% hematocrit, 100 or 200 μL)
with 18F-FDG solution (10–20 μL) due to high viscosity.
In addition, some RBCs in high-hematocrit RBC sus-
pension dried up around fluid surface during long incu-
bation. Therefore, hematocrit was set at 70% in other
labeling studies. LE steadily increased during the incu-
bation with 18F-FDG, reaching a plateau in 50 min
(Fig. 1c). Consequently, the total amount of radioactiv-
ity in the RBCs showed a peak from 30 to 40 min due
to beta decay of 18F (Fig. 1d). As a result, the optimal
incubation (labeling) time with 18F-FDG was considered
to be 30 min.
In the stability studies in vitro, 18F-FDG-labeled RBCs
gradually released 18F-FDG at 37 °C for at least 3 h
(Fig. 2). Since the released 18F-FDG would be excreted
in urine or taken up by extravascular tissues after injection,
BPI with 18F-FDG-labeled RBCs should be performed as
early as possible after equilibrium in the blood is achieved.
While the retention rate of 18F-FDG in the in vitro assess-
ment was 89.9% at 60 min (Fig. 2a), that of the stability
studies in the in vivo assessment was 94.4% at 60 min
(Fig. 4b). Therefore, we concluded that 18F-FDG-labeledmaging of rats
Fig. 4 Whole body data of normal rats in 18F-FDG-labeled RBC PET. a Representative serial maximum-intensity-projection images after intravenous
injection for 120 min of 18F-FDG-labeled RBCs. Cardiac cavities and vascular system were clearly visualized. H heart, IVC inferior vena cava, Sp spleen,
UB urinary bladder. b Time-activity curves of the organs during PET imaging for 120 min (n = 5)
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BPI.
We found that keeping the labeled RBCs at 0 °C pre-
vented the 18F-FDG release. Thus, the preparation after
the incubation with 18F-FDG should be performed at 0°
in case of a long time interval between the preparation
and injection. Actually, we performed pre-injection cool-
ing and rewarming just before injection for in vivo
studies.
Based on the results of TLC, the radioactive substances
inside 18F-FDG-labeled RBCs during the incubation in
plasma were almost all non-FDG (Fig. 2b). Radioactivity
in the intracellular fluid was likely to represent 18F-FDG-
6-phosphate because of the phosphorylation by hexoki-
nase in RBCs. In addition, the fact that RBCs have no
radioactivity of glucose-6-phosphatase [26] would account
for the small amount (<5% in 60 min after incubation) of
18F-FDG. However, the exact mechanism for increasing
extracellular 18F-FDG (i.e., the labeled RBCs continued to
release 18F-FDG) over 180 min was unknown. There
might be a glucose-6-phosphatase-independent mechan-
ism as suggested in some tumor cells [27].
An optimal labeling procedure for the in vivo imaging
of rats is shown in Fig. 3. After injecting 18F-FDG-
labeled RBCs intravenously, PET images exhibited
marked contrast for the blood pool (Fig. 4a). TACs
showed that the radioactivity of most organs was nearly
unchanged after equilibrium was achieved (Fig. 4b).Since we used in vitro labeling technique, denaturation of
the labeled RBCs may be suspected. However, whether
18F-FDG-labeled RBCs were denaturated was unknown
because splenic radioactivity was not as high as typically
seen in denaturation of the labeled RBCs. Splenic radio-
activity depends not only on denaturation of RBCs but
also on splenic sequestration of RBCs [28]. Furthermore,
splenic sequestration is influenced by adrenergic agonists
[28, 29] and isoflurane anesthesia [29]. Thus, the elevation
of splenic radioactivity in the present study did not neces-
sarily mean the occurrence of RBC denaturation. Splenic
radioactivity of our normal rats during 30 min after injec-
tion (Fig. 4b) was almost the same as that of the previous
study using 11C-CO-labeled RBCs in rats [13], in which
splenic radioactivity was higher than hepatic radioactivity
and lower than pulmonary radioactivity during 30 min
after agent administration. Since the labeling procedure of
11C-CO-labeled RBCs is only an inhalation of 11C-CO gas,
splenic radioactivity of 11C-CO-labeled RBCs would not
be affected by RBC denaturation. Therefore, it is consid-
ered that the 18F-FDG-labeled RBCs produced in our pro-
cedure would be as stable as 11C-CO-labeled RBCs in rats.
In the intraabdominal bleeding models, the extravascu-
lar blood was three-dimensionally identified on the PET
images and the dynamic change of extravascular radio-
activity was observed (Figs. 5 and 6). Although this was
challenging, we tried to measure the change of extra-
vascular radioactivity in the two different intraabdominal
Fig. 5 18F-FDG-labeled RBC PET in a temporary intraabdominal bleeding model. a Maximum-intensity-projection images in pre- (left), post- (middle)
bleeding phase, and the subtracted (right) image between them. The radioactivity in the urinary bladder is seen in the images (arrows). b PET, CT, and
fused PET/CT axial images at lower level of the abdomen. Intraabdominal bleeding is identified as high radioactivity in the extravascular space in the
fused image (arrowheads). c Time-activity curve of extravascular radioactivity in the subtracted image. The radioactivity appeared soon after the manual
puncture of the colonic wall (22 min), and then it reached a plateau about 5 min later
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rate as well as the bleeding point or volume can influence
treatment strategy for intraabdominal bleeding in human
practice [1]. The differences in aggressiveness or time
course of intraabdominal bleeding could be observed with
18F-FDG-labeled RBC PET, although the quantitative ac-
curacy was not confirmed in the present study. Future
evaluation is needed to support this potential way to use
18F-FDG-labeled RBC PET.
Labeling RBCs with 18F-FDG should be of greater
value than the other PET tracers because of the over-
whelming availability and accessibility of 18F-FDG. How-
ever, there are some limitations to our method. First,
in vitro labeling is troublesome due to the necessity of
blood sampling and labeling procedure, the requirement
for a clean space, and the radiation exposure for opera-
tors. We may be able to simplify the labeling procedures
by reducing the number of washes or by shortening theduration of glucose deprivation. In the present study, we
introduced the surest way to obtain BPI using 18F-FDG.
Further evaluation regarding simplification of the labeling
technique is needed. Second, 18F-FDG-labeled RBC PET
has many issues towards clinical applications in contrast
to 99mTc-labeled RBC scintigraphy. Although RBCs can be
labeled with 99mTc with the in vivo method [30], it seems
to be impossible to label RBCs with 18F-FDG in vivo.
Given the short half-life of 18F, it is unlikely that any insti-
tution would have a dose available for an emergency GI
bleeding study at midnight. Even at daytime, it is not easy
to keep 18F-FDG available for unpredictable emergency
procedures. Thus, 18F-FDG-labeled RBC PET is challen-
ging for clinical translation at present.
Conclusions
We presented an optimal labeling procedure of 18F-FDG-
labeled RBCs for BPI. Among the factors that influenced
Fig. 6 18F-FDG-labeled RBC PET in a persistent intraabdominal bleeding model. a Maximum-intensity-projection images in pre- (left) and
post- (middle) bleeding phase and the subtracted (right) image between them. The subtracted image shows massive bleeding in the right
side of the abdomen (arrowheads). b PET, CT, and fused PET/CT axial images at the middle level of the abdomen. CT shows an area of fluid
collection, and the fused image shows high radioactivity in the corresponding area (arrows). c Time-activity curve of extravascular radioactivity in the
subtracted image. The radioactivity was continuously increased after the manual puncture of the colonic wall (22 min)
Matsusaka et al. EJNMMI Research  (2017) 7:19 Page 9 of 10LE, we found that glucose deprivation dramatically in-
creased LE. Although a slight fraction of 18F-FDG was re-
leased from 18F-FDG-labeled RBCs, 18F-FDG-labeled RBC
PET images revealed that the cardiovascular system of
normal rats was clearly and stably visualized for several
hours. In the intraabdominal bleeding models, the extra-
vascular blood was clearly visualized on PET and the dy-
namic change of extravascular radioactivity was evaluated.
There is the need for further research to determine the
potential of 18F-FDG-labeled RBCs as a clinical agent for
BPI in humans.Additional file
Additional file 1: Figure S1. Relationship between the radioactivity of
added 18F-FDG and the actual radioactivity of 18F-FDG-labeled RBCs.
Positive linear correlation between them was found (some dots overlap).
Figure S2. Extracellular glucose concentration during a 180-min incubationof 18F-FDG-labeled RBCs in non-radioactive plasma at 37 °C and at 0 °C
(n = 4). Figure S3. Representative microscopic appearance of 18F-FDG-
labeled RBCs sampled just before injection. Abnormal RBCs were not
identified. (DOCX 330 kb)Abbreviations
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